Publishing

Papers, posters and Newsletters

01.

Papers

#

YEAR

TITLE

VIEW

1

2020

LR-COVID-19

2

2020

General Medicine

3

2017

Reference Pricing

4

2020

Simple FAQs for COVID-19:

5

2020

Types of RSAs

6

2017

Sources of information and critical assessment

7

2017

A network cost effectivness meta-analysis a network

8

2017

Assessment of health technologies for advanced sarcom

9

2016

Analysis and assessment of the targeted health

10

2016

Cost-effectivness analysis of MS

11

2017

Alternative biologic drug therapies for the treatment of plaque

02.

Posters

#

YEAR

TITLE

VIEW

1

2018

Budget impact analysis of palbociclib

2

2018

Budget impact analysis of tafluprost/timolol maleate

3

2018

Budget impact analysis of cladribine tablets

4

2018

Cost-effectiveness analysis of cladribine

5

2018

Cost-effectiveness analysis of palbociclib

6

2018

Cost-minimization analysis

7

2018

Budget impact analysis of Cariprazine

8

2018

Comparative effectiveness of pan-genotypic therapies

9

2018

Analysis and assessment of the targeted healtCost-effectiveness analysis of inotuzumabh

10

2019

EUROQOL 5D assessed health related quality of life in cancer patients vs. general population in bulgaria

11

2019

EQ5D5L Bulgarian data

12

2019

Cost effectiveness analysis of ceftazidime/avibactam for the treatment of adults with complicated urinary tract infections in Bulgaria

13

2019

Budget impact analysis of ceftazidime.avibactam

14

2020

Differences and Similarities in the LEVEL of Evidentiary Requirements Required for Orphan Drugs during HTA Appraisal in CEE Countries

15

2020

Differences and Similarities in the LEVEL of Clinical Evidentiary Requirements Required for Orphan Drugs during HTA Appraisal in Bulgaria, France, Germany, Sweden, and the UK

16

2020

Multi-criteria decision analysis on the inclusion of orphan drugs for reimbursement in Bulgaria, France, Germany, Sweden, UK

17

2020

Multi-criteria decision analysis on the inclusion of orphan drugs for reimbursement in selected CEE countries

18

2020

A comparative analysis on application of managed entry agreements

19

2020

Differences and Similarities in the Principles

20

2020

Differences and Similarities in the LEVEL of Evidentiary Requirements Required for Orphan Drugs during HTA Appraisal between CEE Countries and the Top Three Leading EU Economies

21

2020

Pharmacoeconomic evaluation of drug therapies for treatment

22

2020

Assessment of Comparative Effectiveness of Next Generation Sequencing Versus Standard Diagnostic TESTS in Patients with NON-SMALL CELL LUNG Cancer

23

2020

A Systematic Literature Review on Cost-Effectiveness

03.

Newsletters

#

YEAR


TITLE

VIEW

1

02/2021

Споразумения за споделяне на риска

2

03/2021

Кратък преглед на приложението на сср в избрани европейски страни с фокус върху лекарства-сираци

3

04/2021

Обзорни анализи

4

05/2021

Иновативни модели, използвани за заплащане на генни терапии, в световен мащаб

5

06/2021

HEMS HTA Review

6

09/2021

ISPOR ABSRACTS HTA Review

Contact us